Drug Trial Radar · NCT00785785
A Study of Nilotinib Versus Imatinib in GIST Patients
Last checked: Nov 19, 2026Latest source record: Jun 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
644
Actual
Start
Mar 2009
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Conditions
- Gastrointestinal Stromal Tumor (GIST)
Interventions
Nilotinib (AMN107)Drug
imatinib (STI571)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Progression Free Survival (PFS)Time frame: up to month 37
Locations
165 sites in 35 countries. Site status is shown where the registry gives one.
Birmingham Hematology and Oncology Associates
Birmingham, Alabama
Northern Arizona Hematology/Oncology Associates, P.C. Dept. of No. AZ Hem-Onc
Flagstaff, Arizona
City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(4)
Duarte, California
City of Hope National Medical Center Regulatory Document
Duarte, California
University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (2)
La Jolla, California
University of California at Los Angeles GI Oncology Program
Los Angeles, California
Stanford University Medical Center Stanford Cancer Center
Stanford, California
University of Colorado Dept. of Univ. of Colorado
Aurora, Colorado
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer
Greenwood Village, Colorado
Washington Hospital Center Wash Hospital
Washington D.C., District of Columbia
Ocala Oncology Center Dept. of Ocala Oncology Center
Ocala, Florida
Kootenai Medical Center Dept.ofKootenai Med.Ctr.
Coeur d'Alene, Idaho
Northwestern University Clinical Research Office (2)
Chicago, Illinois
Dana Farber Cancer Institute Centerfor Sarcoma&BoneOncology
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center DeptofMichiganCancerCenter(6)
Ann Arbor, Michigan
Minnesota Oncology Hematology, P.A. SC
Minneapolis, Minnesota
Mayo Clinic - Rochester Division of Hematology
Rochester, Minnesota
New York Oncology Hematology, P.C. NYOH Amsterdam
Troy, New York
New York Oncology Hematology, P.C. NYOH@AlbanyMedicalCenter(2)
Troy, New York
University of Pennsylvania Medical Center CAMN107G2301
Philadelphia, Pennsylvania
Vanderbilt Univeristy Ingram Cancer Ctr.
Nashville, Tennessee
Texas Oncology, P.A. Tex Onc (2)
Bedford, Texas
Texas Oncology Wichita Falls
Dallas, Texas
University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3)
Dallas, Texas
University of Texas/MD Anderson Cancer Center Dept. of MD Anderson (13)
Houston, Texas
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
San Antonio, Texas
Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
Tyler, Texas
University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(3)
Salt Lake City, Utah
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Leoben, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Wels, Austria
Novartis Investigative Site
Innsbruck, Tyrol, Austria
Novartis Investigative Site
Uberlândia, Minas Gerais, Brazil
Novartis Investigative Site
Florianópolis, Santa Catarina, Brazil
Novartis Investigative Site
Campinas, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.